# PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)

> **NCT03492931** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 21 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Ticagrelor

## Key facts

- **NCT ID:** NCT03492931
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2019-05-07
- **Final completion:** 2019-05-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492931, "PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03492931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*